146 related articles for article (PubMed ID: 2003987)
1. Serum DU-PAN-2 in the differential diagnosis of pancreatic cancer: influence of jaundice and liver dysfunction.
Fabris C; Malesci A; Basso D; Bonato C; Del Favero G; Tacconi M; Meggiato T; Fogar P; Panozzo MP; Ferrara C
Br J Cancer; 1991 Mar; 63(3):451-3. PubMed ID: 2003987
[TBL] [Abstract][Full Text] [Related]
2. DU-PAN-2 levels in serum and pancreatic ductal fluids of patients with benign and malignant pancreatic disease.
Mahvi DM; Seigler HF; Meyers WC; Kalthoff H; Schmiegel WH; Metzgar RS
Pancreas; 1988; 3(4):488-93. PubMed ID: 3174610
[TBL] [Abstract][Full Text] [Related]
3. Comparison of two newly identified tumor markers (CAR-3 and DU-PAN-2) with CA 19-9 in patients with pancreatic cancer.
Ferrara C; Basso D; Fabris C; Malesci A; Fogar P; Meggiato T; Panozzo MP; Scalon P; Del Favero G; Plebani M
Tumori; 1991 Feb; 77(1):56-60. PubMed ID: 1673269
[TBL] [Abstract][Full Text] [Related]
4. Comparative studies of DU-PAN-2, carcinoembryonic antigen, and CA19-9 in the serum and bile of patients with pancreatic and biliary tract diseases: evaluation of the influence of obstructive jaundice.
Ohshio G; Manabe T; Watanabe Y; Endo K; Kudo H; Suzuki T; Tobe T
Am J Gastroenterol; 1990 Oct; 85(10):1370-6. PubMed ID: 2220731
[TBL] [Abstract][Full Text] [Related]
5. [Is jaundice a cause of error in the interpretation of CA 19-9 blood levels?].
Nakad A; Colombel JF; Geubel AP; Cerulus G; Farchakh E; Degrez T; Janssen J; Cortot A; Paris JC; Dive C
Acta Gastroenterol Belg; 1989; 52(1-2):17-22. PubMed ID: 2618531
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of CA 19-9 as a serum tumour marker in pancreatic cancer.
Haglund C; Roberts PJ; Kuusela P; Scheinin TM; Mäkelä O; Jalanko H
Br J Cancer; 1986 Feb; 53(2):197-202. PubMed ID: 3456787
[TBL] [Abstract][Full Text] [Related]
7. Correlative study on expression of CA 19-9 and DU-PAN-2 in tumor tissue and in serum of pancreatic cancer patients.
Takasaki H; Uchida E; Tempero MA; Burnett DA; Metzgar RS; Pour PM
Cancer Res; 1988 Mar; 48(6):1435-8. PubMed ID: 3162196
[TBL] [Abstract][Full Text] [Related]
8. Usefulness of a new tumor marker, Span-1, for the diagnosis of pancreatic cancer.
Kiriyama S; Hayakawa T; Kondo T; Shibata T; Kitagawa M; Ono H; Sakai Y
Cancer; 1990 Apr; 65(7):1557-61. PubMed ID: 2311067
[TBL] [Abstract][Full Text] [Related]
9. [Detection of DU-PAN-2 antigen (pancreatic cancer-associated antigen) in sera of patients with cancer of the digestive tract].
Takami H; Furuuchi T; Ogata Y; Abe O
Gan To Kagaku Ryoho; 1986 Oct; 13(11):3207-14. PubMed ID: 3777958
[TBL] [Abstract][Full Text] [Related]
10. CA 19-9 and CA 50 in benign and malignant pancreatic and biliary diseases.
Paganuzzi M; Onetto M; Marroni P; Barone D; Conio M; Aste H; Pugliese V
Cancer; 1988 May; 61(10):2100-8. PubMed ID: 2834038
[TBL] [Abstract][Full Text] [Related]
11. Detection of an oncofetal antigen (DU-PAN-2) in sera of patients with non-malignant hepatobiliary diseases and hepatomas.
Haviland AE; Borowitz MJ; Killenberg PG; Lan MS; Metzgar RS
Int J Cancer; 1988 Jun; 41(6):789-93. PubMed ID: 2836318
[TBL] [Abstract][Full Text] [Related]
12. How does liver dysfunction influence serum CA 19-9 in pancreatic cancer?
Basso D; Fabris C; Del Favero G; Piccoli A; Angonese C; Pasquali C; Castoro C; Plebani M; Leandro G; Burlina A
Ital J Gastroenterol; 1990 Feb; 22(1):1-6. PubMed ID: 2131920
[TBL] [Abstract][Full Text] [Related]
13. Serum CA 50 as a tumor marker in pancreatic cancer: a comparison with CA 19-9.
Haglund C; Kuusela P; Jalanko H; Roberts PJ
Int J Cancer; 1987 Apr; 39(4):477-81. PubMed ID: 3470260
[TBL] [Abstract][Full Text] [Related]
14. Measurement of a pancreatic cancer-associated antigen (DU-PAN-2) detected by a monoclonal antibody in sera of patients with digestive cancers.
Sawabu N; Toya D; Takemori Y; Hattori N; Fukui M
Int J Cancer; 1986 May; 37(5):693-6. PubMed ID: 3457770
[TBL] [Abstract][Full Text] [Related]
15. Carbohydrate antigen 19-9 (CA 19-9) and carcinoembryonic antigen (CEA) in pancreatic cancer. Role of age and liver dysfunction.
Del Favero G; Fabris C; Panucci A; Basso D; Plebani M; Baccaglini U; Leandro G; Burlina A; Naccarato R
Bull Cancer; 1986; 73(3):251-5. PubMed ID: 3530354
[TBL] [Abstract][Full Text] [Related]
16. Comparative studies on the expression of tumor-associated glycoprotein (TAG-72), CA 19-9 and DU-PAN-2 in normal, benign and malignant pancreatic tissue.
Takasaki H; Tempero MA; Uchida E; Büchler M; Ness MJ; Burnett DA; Metzgar RS; Colcher D; Schlom J; Pour PM
Int J Cancer; 1988 Nov; 42(5):681-6. PubMed ID: 3053465
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical studies on the localization of cancer associated antigens DU-PAN-2 and CA19-9 in carcinomas of the digestive tract.
Ohshio G; Ogawa K; Kudo H; Yamabe H; Nakashima Y; Kim YC; Endo K; Watanabe Y; Manabe T; Tobe T
J Gastroenterol Hepatol; 1990; 5(1):25-31. PubMed ID: 2103381
[TBL] [Abstract][Full Text] [Related]
18. [Determination of serum DU-PAN-2 by enzyme immunoassay in patients with various digestive cancers].
Takemori Y; Sawabu N; Satomura Y; Ohta H; Watanabe H; Okai T; Mai M; Hattori N; Akiyama T; Hashimoto T
Gan To Kagaku Ryoho; 1987 Jan; 14(1):119-26. PubMed ID: 3541791
[TBL] [Abstract][Full Text] [Related]
19. [Diagnostic usefulness and limitation of measuring pancreatic cancer associate antigen, SPan-1, in patients with pancreatic cancer].
Satake K; Chung YS; Umeyama K; Takeuchi T; Kim YS
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-1):1139-46. PubMed ID: 2730018
[TBL] [Abstract][Full Text] [Related]
20. [Clinical significance of serum DU-PAN-2 surveyed by solid-phase sandwich EIA for DU-PAN-2].
Ishii M; Urabe T; Seino Y
Gan To Kagaku Ryoho; 1987 Jun; 14(6 Pt 1):1860-5. PubMed ID: 3296960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
